Autonomix Medical, Inc. (NASDAQ:AMIX) Short Interest Down 46.1% in August

Autonomix Medical, Inc. (NASDAQ:AMIX) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totaling 58,624 shares, a drop of 46.1% from the August 15th total of 108,801 shares. Based on an average daily volume of 4,225,824 shares, the short-interest ratio is currently 0.0 days. Approximately 6.4% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on AMIX shares. Zacks Research upgraded Autonomix Medical to a “hold” rating in a report on Tuesday, June 2nd. Wall Street Zen cut Autonomix Medical from a “sell” rating to a “strong sell” rating in a report on Monday. Finally, Weiss Ratings upgraded Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $42.00.

Autonomix Medical Stock Performance

Shares of Autonomix Medical stock opened at $4.12 on Thursday. Autonomix Medical has a 52-week low of $2.44 and a 52-week high of $32.55. The company has a fifty day moving average of $5.78 and a 200-day moving average of $7.22. The stock has a market capitalization of $4.00 million, a price-to-earnings ratio of -0.10 and a beta of -1.00.

Autonomix Medical (NASDAQ:AMIX) last issued its earnings results on Wednesday, August 12th. The company reported ($5.02) EPS for the quarter, topping analysts’ consensus estimates of ($6.40) by $1.38. On average, equities research analysts forecast that Autonomix Medical will post -20.17 earnings per share for the current fiscal year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.